Gunma, Japan

Keigo Endo


 

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 17(Granted Patents)


Location History:

  • Maebashi, JP (2012)
  • Gunma, JP (2013 - 2015)

Company Filing History:


Years Active: 2012-2015

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):

Title: Keigo Endo: Innovator in Cancer Therapy

Introduction

Keigo Endo is a prominent inventor based in Gunma, Japan. He has made significant contributions to the field of cancer therapy through his innovative research and development of monoclonal antibodies. With a total of 4 patents to his name, Endo is recognized for his dedication to advancing medical science.

Latest Patents

One of his latest patents is titled "Tumor-targeting monoclonal antibodies to FZD10 and uses thereof." This invention relates to an antibody or a fragment capable of binding to a Frizzled homologue 10 (FZD10) protein. It includes various forms such as mouse monoclonal antibodies, chimeric antibodies, and humanized antibodies. The patent also outlines methods for treating and preventing FZD10-associated diseases, as well as diagnostic and imaging techniques for FZD10 in subjects.

Another significant patent is "Anti-CDH3 antibodies and uses thereof." This invention focuses on anti-CDH3 antibodies that can be labeled with a radioisotope. The patent provides methods and pharmaceutical compositions that utilize anti-CDH3 antibodies as active ingredients. Given that CDH3 is strongly expressed in various cancer cells, this invention holds promise for therapies targeting pancreatic, lung, colon, prostate, breast, gastric, or liver cancers.

Career Highlights

Keigo Endo is currently associated with Oncotherapy Science, Incorporated, where he continues to work on groundbreaking cancer therapies. His research has the potential to transform treatment options for patients suffering from various types of cancer.

Collaborations

Endo collaborates with notable colleagues such as Yusuke Nakamura and Toyomasa Katagiri, contributing to a dynamic research environment focused on innovative cancer treatments.

Conclusion

Keigo Endo's work in developing targeted therapies through monoclonal antibodies exemplifies the impact of innovation in the medical field. His contributions are paving the way for more effective cancer treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…